India — Maharashtra Food and Drug Administration
Tracked across 6 events · 91 articles · First seen Jul 11, 2026 · Last active Aug 29, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: The regulator enforced public health measures by barring sale, seizing stock, and ordering recall of Cadila Pharmaceuticals' drugs due to deceptive branding.
Jul 11, 2026 · 8 articles
Regulatory
Impact: Issued the comprehensive compliance order, strengthening its regulatory oversight and potentially enhancing its reputation for enforcing blood safety standards.
Aug 07, 2026 · 6 articles
Regulatory
Impact: The FDA was criticized by the India — Bombay High Court for its drastic and procedurally flawed actions. It agreed to revoke its orders against Cadila and follow due process, which may affect its enforcement credibility.
Aug 11, 2026 · 9 articles
Regulatory
Impact: The regulator conducted the inspections and enforcement actions, strengthening its oversight role and potentially enhancing public trust in its operations.
Aug 11, 2026 · 10 articles
Regulatory
Impact: The FDA's enforcement actions are being scrutinized by the court, which criticized its approach. The agency must file an affidavit and oversee the disposal, but its credibility is somewhat challenged.
Aug 10, 2026 · 6 articles
Regulatory
Impact: The Maharashtra FDA enforced regulatory action by cancelling Cipla's licences, reinforcing its stance on drug safety. This action may enhance the regulator's credibility but could also increase scrutiny on other pharmaceutical companies.
Aug 28, 2026 · 52 articles
Tukaram Mundhe
commissioner
↔
India — Maharashtra Food and Drug Administration
Tukaram Mundhe serves as the Commissioner of the Maharashtra Food and Drug Admin
ERGEN INTELLIGENCE
Track India — Maharashtra Food and Drug Administration live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard